image
Consumer Defensive - Household & Personal Products - NYSE - US
$ 26.41
-5.1 %
$ 5.65 B
Market Cap
48.75
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HIMS stock under the worst case scenario is HIDDEN Compared to the current market price of 26.4 USD, Hims & Hers Health, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HIMS stock under the base case scenario is HIDDEN Compared to the current market price of 26.4 USD, Hims & Hers Health, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HIMS stock under the best case scenario is HIDDEN Compared to the current market price of 26.4 USD, Hims & Hers Health, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HIMS

image
$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
1.48 B REVENUE
69.32%
61.9 M OPERATING INCOME
310.18%
126 M NET INCOME
635.28%
251 M OPERATING CASH FLOW
241.69%
-19 M INVESTING CASH FLOW
-57.34%
-108 M FINANCING CASH FLOW
-839.83%
481 M REVENUE
19.82%
18.6 M OPERATING INCOME
-16.89%
26 M NET INCOME
-65.57%
86.4 M OPERATING CASH FLOW
1.31%
-17.2 M INVESTING CASH FLOW
-65.22%
-13.7 M FINANCING CASH FLOW
64.83%
Balance Sheet Hims & Hers Health, Inc.
image
Current Assets 396 M
Cash & Short-Term Investments 300 M
Receivables 0
Other Current Assets 95.6 M
Non-Current Assets 312 M
Long-Term Investments 0
PP&E 93 M
Other Non-Current Assets 219 M
42.44 %13.51 %13.14 %30.92 %Total Assets$707.5m
Current Liabilities 221 M
Accounts Payable 91.2 M
Short-Term Debt 1.89 M
Other Current Liabilities 128 M
Non-Current Liabilities 9.46 M
Long-Term Debt 9.46 M
Other Non-Current Liabilities 0
39.50 %55.58 %4.10 %Total Liabilities$230.8m
EFFICIENCY
Earnings Waterfall Hims & Hers Health, Inc.
image
Revenue 1.48 B
Cost Of Revenue 303 M
Gross Profit 1.17 B
Operating Expenses 1.11 B
Operating Income 61.9 M
Other Expenses -64.1 M
Net Income 126 M
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m001b(303m)1b(1b)62m64m126mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.45% GROSS MARGIN
79.45%
4.19% OPERATING MARGIN
4.19%
8.54% NET MARGIN
8.54%
26.44% ROE
26.44%
17.81% ROA
17.81%
22.29% ROIC
22.29%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Hims & Hers Health, Inc.
image
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)20192019202020202021202120222022202320232024202420252025
Net Income 126 M
Depreciation & Amortization 17.1 M
Capital Expenditures -41.7 M
Stock-Based Compensation 92.3 M
Change in Working Capital 78.6 M
Others 75.2 M
Free Cash Flow 209 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Hims & Hers Health, Inc.
image
Wall Street analysts predict an average 1-year price target for HIMS of $24.3 , with forecasts ranging from a low of $13 to a high of $68 .
HIMS Lowest Price Target Wall Street Target
13 USD -50.78%
HIMS Average Price Target Wall Street Target
24.3 USD -8.01%
HIMS Highest Price Target Wall Street Target
68 USD 157.48%
Price
Max Price Target
Min Price Target
Average Price Target
7070606050504040303020201010Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Hims & Hers Health, Inc.
image
Sold
0-3 MONTHS
37.8 M USD 8
3-6 MONTHS
46.9 M USD 8
6-9 MONTHS
29.1 M USD 7
9-12 MONTHS
50.2 M USD 8
Bought
0 USD 0
0-3 MONTHS
132 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.95 M USD 1
9-12 MONTHS
7. News
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store. zacks.com - 1 week ago
Hims & Hers: Top Pick For The Next Decade Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company. seekingalpha.com - 1 week ago
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension. zacks.com - 1 week ago
Investment strategist picks 3 ‘new age' healthcare stocks to buy Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors. finbold.com - 1 week ago
Bull of the Day: Hims & Hers Health (HIMS) Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. zacks.com - 2 weeks ago
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day. zacks.com - 2 weeks ago
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks. zacks.com - 2 weeks ago
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance. zacks.com - 2 weeks ago
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day. zacks.com - 3 weeks ago
Hims' Weight Loss Expansion: Real Growth or Just Hype? One of the more hotly debated stocks in the market, Hims & Hers Health NYSE: HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly's NYSE: LLY blockbuster weight loss drug. marketbeat.com - 3 weeks ago
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 3 weeks ago
Why Hims & Hers Health Stock Couldn't Beat the Market Today Hims & Hers Health (HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects. fool.com - 4 weeks ago
8. Profile Summary

Hims & Hers Health, Inc. HIMS

image
COUNTRY US
INDUSTRY Household & Personal Products
MARKET CAP $ 5.65 B
Dividend Yield 0.00%
Description Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Contact 2269 Chestnut Street, San Francisco, CA, 94123 https://www.forhims.com
IPO Date Sept. 13, 2019
Employees 1637
Officers Mr. Andrew Dudum Co-Founder, Chairman & Chief Executive Officer Dr. Patrick Carroll M.D. Chief Medical Officer & Director Mr. Oluyemi Okupe Chief Financial Officer Dr. Peter Stahl M.D. Senior Vice President of Men's Reproductive & Sexual Health Ms. Soleil Teubner Boughton J.D. Chief Legal Officer & Corporate Secretary Dr. Daniel Lieberman M.D. Senior Vice President of Mental Health Ms. Melissa Baird Chief Operating Officer Ms. Irene A. Becklund Senior Vice President, Controller & Principal Accounting Officer Ms. Khobi Brooklyn Chief Communications Officer Mr. Mike Chi Chief Commercial Officer